
Michael A Eller

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9050826/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	DC-SIGN (CD209) Mediates Dengue Virus Infection of Human Dendritic Cells. Journal of Experimental Medicine, 2003, 197, 823-829.	8.5	766
2	Effect of Human Immunodeficiency Virus Type 1 (HIVâ€1) Subtype on Disease Progression in Persons from Rakai, Uganda, with Incident HIVâ€1 Infection. Journal of Infectious Diseases, 2008, 197, 707-713.	4.0	230
3	Prospective Study of Acute HIV-1 Infection in Adults in East Africa and Thailand. New England Journal of Medicine, 2016, 374, 2120-2130.	27.0	229
4	Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study. Lancet Infectious Diseases, The, 2015, 15, 905-912.	9.1	193
5	T-bet+ B cells are induced by human viral infections and dominate the HIV gp140 response. JCI Insight, 2017, 2, .	5.0	164
6	Human Dendritic Cells as Targets of Dengue Virus Infection. Journal of Investigative Dermatology Symposium Proceedings, 2001, 6, 219-224.	0.8	149
7	The CD4 ^{â^'} CD8 ^{â^'} MAIT cell subpopulation is a functionally distinct subset developmentally related to the main CD8 ⁺ MAIT cell pool. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E11513-E11522.	7.1	147
8	Circulating HIV-Specific Interleukin-21+CD4+ T Cells Represent Peripheral Tfh Cells with Antigen-Dependent Helper Functions. Immunity, 2016, 44, 167-178.	14.3	104
9	A Phase 1/2 Study of a Multiclade HIVâ€1 DNA Plasmid Prime and Recombinant Adenovirus Serotype 5 Boost Vaccine in HIVâ€Uninfected East Africans (RV 172). Journal of Infectious Diseases, 2010, 201, 600-607.	4.0	100
10	HIV-1 Viral Subtype Differences in the Rate of CD4+ T-Cell Decline Among HIV Seroincident Antiretroviral Naive Persons in Rakai District, Uganda. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 54, 180-184.	2.1	90
11	Reference Intervals in Healthy Adult Ugandan Blood Donors and Their Impact on Conducting International Vaccine Trials. PLoS ONE, 2008, 3, e3919.	2.5	75
12	Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet HIV,the, 2019, 6, e297-e306.	4.7	73
13	Cooperativity of HIV-Specific Cytolytic CD4 T Cells and CD8 T Cells in Control of HIV Viremia. Journal of Virology, 2015, 89, 7494-7505.	3.4	70
14	Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infection. PLoS Pathogens, 2017, 13, e1006510.	4.7	63
15	Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial. Journal of Infectious Diseases, 2017, 215, 1255-1263.	4.0	57
16	Cellular Immune Activation in Cerebrospinal Fluid From Ugandans With Cryptococcal Meningitis and Immune Reconstitution Inflammatory Syndrome. Journal of Infectious Diseases, 2015, 211, 1597-1606.	4.0	55
17	Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5 naturally exposed and recombinant Ad5-HIV vaccinated individuals. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 13439-13444.	7.1	49
18	Elevated Natural Killer Cell Activity Despite Altered Functional and Phenotypic Profile in Ugandans With HIV-1 Clade A or Clade D Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 51, 380-389.	2.1	46

#	Article	IF	CITATIONS
19	A transmission-virulence evolutionary trade-off explains attenuation of HIV-1 in Uganda. ELife, 2016, 5, .	6.0	46
20	Higher HIV-1 Incidence and Genetic Complexity Along Main Roads in Rakai District, Uganda. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 43, 440-445.	2.1	44
21	Transcriptomic signatures of NK cells suggest impaired responsiveness in HIV-1 infection and increased activity post-vaccination. Nature Communications, 2018, 9, 1212.	12.8	44
22	Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption. Nature Medicine, 2020, 26, 498-501.	30.7	43
23	Differential Inhibitory Receptor Expression on T Cells Delineates Functional Capacities in Chronic Viral Infection. Journal of Virology, 2017, 91, .	3.4	39
24	Dynamic MAIT cell response with progressively enhanced innateness during acute HIV-1 infection. Nature Communications, 2020, 11, 272.	12.8	38
25	Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challenge. PLoS Pathogens, 2020, 16, e1008764.	4.7	37
26	Innate and Adaptive Immune Responses Both Contribute to Pathological CD4 T Cell Activation in HIV-1 Infected Ugandans. PLoS ONE, 2011, 6, e18779.	2.5	36
27	Temporal Dynamics of CD8+ T Cell Effector Responses during Primary HIV Infection. PLoS Pathogens, 2016, 12, e1005805.	4.7	36
28	First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector. Journal of Infectious Diseases, 2018, 218, 633-644.	4.0	35
29	OMIPâ€007: Phenotypic analysis of human natural killer cells. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2012, 81A, 447-449.	1.5	33
30	Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial. Lancet HIV,the, 2020, 7, e238-e248.	4.7	33
31	CD40 Ligand Enhances Dengue Viral Infection of Dendritic Cells: A Possible Mechanism for T Cell-Mediated Immunopathology. Journal of Immunology, 2006, 177, 6497-6503.	0.8	32
32	Detection of HIV-1 Neutralizing Antibodies in a Human CD4+/CXCR4+/CCR5+ T-Lymphoblastoid Cell Assay System. PLoS ONE, 2013, 8, e77756.	2.5	32
33	Preservation of Peripheral T Follicular Helper Cell Function in HIV Controllers. Journal of Virology, 2017, 91, .	3.4	32
34	Distinct biomarker signatures in HIV acute infection associate with viral dynamics and reservoir size. JCI Insight, 2018, 3, .	5.0	32
35	Large-Scale Human Immunodeficiency Virus Rapid Test Evaluation in a Low-Prevalence Ugandan Blood Bank Population. Journal of Clinical Microbiology, 2007, 45, 3281-3285.	3.9	31
36	Limited immune surveillance in lymphoid tissue by cytolytic CD4+ T cells during health and HIV disease. PLoS Pathogens, 2018, 14, e1006973.	4.7	30

#	Article	IF	CITATIONS
37	Relatively Low HIV Infection Rates in Rural Uganda, but with High Potential for a Rise: A Cohort Study in Kayunga District, Uganda. PLoS ONE, 2009, 4, e4145.	2.5	28
38	Evolution of HIV-1 within untreated individuals and at the population scale in Uganda. PLoS Pathogens, 2018, 14, e1007167.	4.7	27
39	Preparation of Clinicalâ€Grade Recombinant Canarypox–Human Immunodeficiency Virus Vaccine–Loaded Human Dendritic Cells. Journal of Infectious Diseases, 2002, 186, 1242-1252.	4.0	26
40	A vaccine-induced gene expression signature correlates with protection against SIV and HIV in multiple trials. Science Translational Medicine, 2019, 11, .	12.4	26
41	Expansion of Inefficient HIV-Specific CD8 T Cells during Acute Infection. Journal of Virology, 2016, 90, 4005-4016.	3.4	25
42	Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA vaccine candidate in healthy Ugandans. Vaccine, 2007, 25, 7737-7742.	3.8	23
43	Safety and Immunogenicity of PENNVAX-G DNA Prime Administered by Biojector 2000 or CELLECTRA Electroporation Device With Modified Vaccinia Ankara-CMDR Boost. Journal of Infectious Diseases, 2017, 216, 1080-1090.	4.0	23
44	Terminal Effector CD8 T Cells Defined by an IKZF2+IL-7Râ^' Transcriptional Signature Express FcγRIIIA, Expand in HIV Infection, and Mediate Potent HIV-Specific Antibody-Dependent Cellular Cytotoxicity. Journal of Immunology, 2019, 203, 2210-2221.	0.8	23
45	Liposome-Encapsulated Human Immunodeficiency Virus-1 gp120 Induces Potent V1V2-Specific Antibodies in Humans. Journal of Infectious Diseases, 2018, 218, 1541-1550.	4.0	22
46	Quality Monitoring of HIV-1-Infected and Uninfected Peripheral Blood Mononuclear Cell Samples in a Resource-Limited Setting. Vaccine Journal, 2010, 17, 910-918.	3.1	20
47	A flow cytometry based assay that simultaneously measures cytotoxicity and monocyte mediated antibody dependent effector activity. Journal of Immunological Methods, 2018, 462, 74-82.	1.4	19
48	HIV Type 1 Disease Progression to AIDS and Death in a Rural Ugandan Cohort Is Primarily Dependent on Viral Load Despite Variable Subtype and T-Cell Immune Activation Levels. Journal of Infectious Diseases, 2015, 211, 1574-1584.	4.0	17
49	Anti-V2 antibodies virus vulnerability revealed by envelope V1 deletion in HIV vaccine candidates. IScience, 2021, 24, 102047.	4.1	16
50	Impaired natural killer cell responses are associated with loss of the highly activated NKG2A+CD57+CD56dim subset in HIV-1 subtype D infection in Uganda. Aids, 2014, 28, 1273-1278.	2.2	15
51	Platelets and Erythrocyte-Bound Platelets Bind Infectious HIV-1 in Plasma of Chronically Infected Patients. PLoS ONE, 2013, 8, e81002.	2.5	15
52	Human Immunodeficiency Virus Type 1 Infection Is Associated with Increased NK Cell Polyfunctionality and Higher Levels of KIR3DL1 ⁺ NK Cells in Ugandans Carrying the HLA-B Bw4 Motif. Journal of Virology, 2011, 85, 4802-4811.	3.4	14
53	Preferential Infection of α4β7+ Memory CD4+ T Cells During Early Acute Human Immunodeficiency Virus Type 1 Infection. Clinical Infectious Diseases, 2020, 71, e735-e743.	5.8	14
54	<scp>OMIP</scp> â€027: Functional analysis of human natural killer cells. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2015, 87, 803-805.	1.5	13

#	Article	IF	CITATIONS
55	RV144 HIV-1 vaccination impacts post-infection antibody responses. PLoS Pathogens, 2020, 16, e1009101.	4.7	13
56	Brief Report. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, 15-20.	2.1	12
57	Expansion of Stem Cell-Like CD4 ⁺ Memory T Cells during Acute HIV-1 Infection Is Linked to Rapid Disease Progression. Journal of Virology, 2019, 93, .	3.4	11
58	High-Throughput High-Resolution Class I HLA Genotyping in East Africa. PLoS ONE, 2010, 5, e10751.	2.5	10
59	Monocyte activation, HIV, and cognitive performance in East Africa. Journal of NeuroVirology, 2020, 26, 52-59.	2.1	9
60	B Cell Compartmentalization in Blood and Cerebrospinal Fluid of HIV-Infected Ugandans with Cryptococcal Meningitis. Infection and Immunity, 2020, 88, .	2.2	9
61	Associations Between Antibody Fc-Mediated Effector Functions and Long-Term Sequelae in Ebola Virus Survivors. Frontiers in Immunology, 2021, 12, 682120.	4.8	9
62	Cerebrospinal fluid CD4+ T cell infection in humans and macaques during acute HIV-1 and SHIV infection. PLoS Pathogens, 2021, 17, e1010105.	4.7	9
63	A Double-Blind Randomized Phase I Clinical Trial Targeting ALVAC-HIV Vaccine to Human Dendritic Cells. PLoS ONE, 2011, 6, e24254.	2.5	8
64	Monocyte and CD4+ T-cell antiviral and innate responses associated with HIV-1 inflammation and cognitive impairment. Aids, 2020, 34, 1289-1301.	2.2	8
65	OMIPâ€046: Characterization of invariant T cell subset activation in humans. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2018, 93, 499-503.	1.5	7
66	Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans. Journal of Virology, 2018, 92, .	3.4	7
67	Biomarkers of Inflammation Correlate With Clinical Scoring Indices in Human Immunodeficiency Virus–Infected Kenyans. Journal of Infectious Diseases, 2019, 219, 284-294.	4.0	7
68	Activated PD-1+ CD4+ T cells represent a short-lived part of the viral reservoir and predict poor immunologic recovery upon initiation of ART. Aids, 2020, 34, 197-202.	2.2	6
69	B Cell Depletion in HIV-1 Subtype A Infected Ugandan Adults: Relationship to CD4 T Cell Count, Viral Load and Humoral Immune Responses. PLoS ONE, 2011, 6, e22653.	2.5	6
70	Single-Cell Level Response of HIV-Specific and Cytomegalovirus-Specific CD4 T Cells Correlate With Viral Control in Chronic HIV-1 Subtype A Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 61, 9-18.	2.1	5
71	Impact of the expression system on the immune responses to self-assembling protein nanoparticles (SAPNs) displaying HIV-1 V1V2 loop. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 29, 102255.	3.3	5
72	Sex and Urbanicity Contribute to Variation in Lymphocyte Distribution across Ugandan Populations. PLoS ONE, 2016, 11, e0146196.	2.5	5

#	Article	IF	CITATIONS
73	Differential Loss of Invariant Natural Killer T Cells and FoxP3+ Regulatory T Cells in HIV-1 Subtype A and Subtype D Infections. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 289-293.	2.1	4
74	A de novo approach to inferring within-host fitness effects during untreated HIV-1 infection. PLoS Pathogens, 2020, 16, e1008171.	4.7	4
75	Increased Inflammation and Liver Disease in HIV/HBV-coinfected Individuals. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, Publish Ahead of Print, 310-313.	2.1	4
76	Ontogeny of CD4 ⁺ T Lymphocytes with Phenotypic Susceptibility to HIV-1 during Exclusive and Non-Exclusive Breastfeeding in HIV-1-exposed Ugandan Infants. Journal of Infectious Diseases, 2017, 215, jiw553.	4.0	3
77	Single-cell Quantitation of mRNA and Surface Protein Expression in Simian Immunodeficiency Virus-infected CD4 ⁺ T Cells Isolated from Rhesus macaques. Journal of Visualized Experiments, 2018, , .	0.3	3
78	Longitudinal Analysis of Peripheral and Colonic CD161+ CD4+ T Cell Dysfunction in Acute HIV-1 Infection and Effects of Early Treatment Initiation. Viruses, 2020, 12, 1426.	3.3	3
79	Cryptic Multiple HIV-1 Infection Revealed by Early, Frequent, and Deep Sampling during Acute Infection. AIDS Research and Human Retroviruses, 2014, 30, A58-A58.	1.1	2
80	Preferential and persistent impact of acute HIV-1 infection on CD4 ⁺ iNKT cells in colonic mucosa. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	2
81	Short Communication: Colony-Forming Hematopoietic Progenitor Cells Are Not Preferentially Infected by HIV Type 1 Subtypes A and Din Vivo. AIDS Research and Human Retroviruses, 2012, 28, 1119-1123.	1.1	1
82	Single-Cell Profiling of Latently SIV-Infected CD4 ⁺ T Cells Directly <i>Ex Vivo</i> to Reveal Host Factors Supporting Reservoir Persistence. Microbiology Spectrum, 2022, 10, e0060422.	3.0	1
83	Susceptibility to HIV-1 Acquisition linked to Malaria Exposure: A Case-control Study. Clinical Infectious Diseases, 0, , .	5.8	0